PCN262 PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL
May 1, 2019, 00:00
10.1016/j.jval.2019.04.383
https://www.valueinhealthjournal.com/article/S1098-3015(19)30575-3/fulltext
Title :
PCN262 PREFERENCE-WEIGHTED HEALTH STATUS IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL; JCAR017) IN THE ONGOING, MULTICENTER, PHASE 1 TRANSCEND NHL 001 TRIAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30575-3&doi=10.1016/j.jval.2019.04.383
First page :
Section Title :
Open access? :
No
Section Order :
10030